Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Aerospace & Defense
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 48.22M shares outstanding
ITGenenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors.
Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Brian R. Leyland-Jones, Ph.D.(1)
Director
Christopher P. Parios (2)
Lead Director
Marvin E. Jaffe, M.D.
Director
Raymond P. Warrell, Jr., M.D.
Chairman and Chief Executive Officer
Employees
9
Country
IT
Sector
Industrials
Website
genenta.com
Loading congressional disclosures…
based on 48.22M shares outstanding
IT30d Avg
67.50K
60d Avg
55.70K
90d Avg
61.82K
